Novel diagnostic method for breast cancer and ovarian cancer
About 5-10 % of all breast cancers are hereditary, and in 30-40% of these cases a mutation in the BRCA1/2 genes can be detected. The tumor biology of carcinomas with BRCA1 mutation differs significantly from sporadic cancers and cases with BRCA2 mutations involved. It is known that in breast cancer tissue shows a significantly higher T3 receptor (Trijodothyronin receptor, THR) binding capacity as compared to normal breast tissue.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…
